Sra-333
Diabetic Neuropathic Pain
Wake Forest UniversityPhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Diabetic Neuropathic Pain cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Duloxetine Aga Khan University | Phase 4 | A |
bay2395840 Bayer | Phase 2 | BB |
Abt-639 AbbVie (prior sponsor, Abbott) | Phase 2 | B |
ELIAPIXANT Bayer | Phase 2 | B |
ly3857210 Eli Lilly and Company | Phase 2 | B |
View all 14 →
Same molecule, other indications
Sra-333 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →